Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 11, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well pregnant women in France follow the new recommendations for preventing respiratory syncytial virus (RSV) infections in their infants. RSV can cause serious respiratory illness in babies, and in France, many infants are hospitalized each year because of it. The study will focus on two main strategies: getting a vaccine during pregnancy that helps protect newborns, or giving a special antibody treatment directly to the baby after birth.
To participate in this trial, women need to be at least 18 years old, able to speak and understand French, and expecting to give birth in France between October 1, 2024, and January 31, 2025. They should be having a healthy baby born at 37 weeks of pregnancy or later. Participants will fill out a questionnaire to share their thoughts and choices regarding the prevention strategies. This study aims to understand how many women choose each option and why, which can help improve future RSV prevention efforts for infants.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18
- • Able to speak and understand French well enough to read and comprehend the information leaflet and the questionnaire
- • Delivery in metropolitan France between October 1, 2024, and January 31, 2025
- • Live-born child
- • Term-born child (37 weeks of gestation or more)
- • No objection to participating in the study
- Exclusion Criteria:
- • Women under legal protection
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported